Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 4
2022 6
2023 8
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Cited In for PMID: 34778690

23 results

Results by year

Filters applied: . Clear all
Page 1
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES. Taza F, et al. JCO Precis Oncol. 2021 Jul 22;5:PO.21.00070. doi: 10.1200/PO.21.00070. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34778690 Free PMC article.
Prostate cancer and PARP inhibitors: progress and challenges.
Teyssonneau D, Margot H, Cabart M, Anonnay M, Sargos P, Vuong NS, Soubeyran I, Sevenet N, Roubaud G. Teyssonneau D, et al. J Hematol Oncol. 2021 Mar 29;14(1):51. doi: 10.1186/s13045-021-01061-x. J Hematol Oncol. 2021. PMID: 33781305 Free PMC article. Review.
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.
Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ, McKay RR, Alva A, Schweizer MT. Graham LS, et al. JCO Precis Oncol. 2024 Aug;8:e2400014. doi: 10.1200/PO.24.00014. JCO Precis Oncol. 2024. PMID: 39178368
PARP inhibitors in metastatic prostate cancer.
Taylor AK, Kosoff D, Emamekhoo H, Lang JM, Kyriakopoulos CE. Taylor AK, et al. Front Oncol. 2023 Apr 24;13:1159557. doi: 10.3389/fonc.2023.1159557. eCollection 2023. Front Oncol. 2023. PMID: 37168382 Free PMC article. Review.
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Orme JJ, et al. Eur Urol Oncol. 2024 Aug;7(4):877-887. doi: 10.1016/j.euo.2023.11.014. Epub 2023 Dec 9. Eur Urol Oncol. 2024. PMID: 38072760
23 results